Ozempic vs. Mounjaro: What's the Difference?

Direct Answer

Ozempic contains semaglutide, Mounjaro contains tirzepatide, different active ingredients from different manufacturers, Novo Nordisk and Eli Lilly respectively. Both are approved for type 2 diabetes, and head-to-head data shows tirzepatide, Mounjaro's active ingredient, tends to produce greater average weight loss as a secondary effect.

Approved Uses

Ozempic is approved for blood sugar control in type 2 diabetes and cardiovascular risk reduction. Mounjaro is approved for blood sugar control in type 2 diabetes and, since a 2025 label update, cardiovascular risk reduction in adults with heart failure with preserved ejection fraction. Neither is approved specifically for weight loss, that's the role of their sister brands, Wegovy and Zepbound.

Dosing

Ozempic is dosed up to 2 mg weekly. Mounjaro uses a titration schedule from 2.5 mg up to a maximum of 15 mg weekly. These aren't directly comparable milligram-for-milligram, since they're different molecules with different potencies.

Which One Might Your Doctor Prescribe

Both are approved, effective options for type 2 diabetes. The choice often comes down to insurance coverage, specific health history, and provider experience, rather than one being universally better.

References

• Ozempic Prescribing Information (FDA)
• Mounjaro Prescribing Information (FDA)

Related Resources

• Semaglutide vs. Tirzepatide
• Ozempic Medication Guide
• Mounjaro Medication Guide

More From DietApp.com

• Injection Tracker
• Prediabetes

Get Started

Download DietApp.com to track your dose and progress, whichever medication your provider recommends.

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.